MedPath

Randomized controlled trial to evaluate the effectiveness of immunotherapy in gastric cancer based on preoperative serum glycoproteins: acute phase reactants (APRs).

Not Applicable
Conditions
Gastric cancer
Registration Number
JPRN-UMIN000037472
Lead Sponsor
Preoperative Serum Glycoproteins Study Group for Immunotherapy in Japan
Brief Summary

PSK therapy has a beneficial effect on gastric cancer patients with high levels of CEA and acute phase reactant (APR).

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
886
Inclusion Criteria

Not provided

Exclusion Criteria

1. Double cancer. 2. Prior cytotoxic or radiation therapy. 3. Abnormal bone marrow, hepatic and renal function 4. Severe cardiac, hepatic and lung failure, and an attending doctor was considered unsuitable.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath